
Developing Innovative Ideas, Creating New Markets
As Managing Director of Asahi Kasei Europe, Hideki Tsutsumi has implemented the Japanese chemical company's growth strategy in Europe.
As Managing Director of Asahi Kasei Europe, Hideki Tsutsumi has implemented the Japanese chemical company's growth strategy in Europe.
Interview with Michael Postlethwaite, Senior Director, Sales & Business Development, European Territories, AmbioPharm
Interview with Christophe Couturier and Claudia Berrón, Avantor
CHEManager Interview with Antti Koivisto and Michael Badine, WeylChem Advanced Intermediates
Michael Reubold talked to Evonik’s Sanjeev Taneja about the role of catalysts in the company and their value to the industry and the society.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The European Chemical Industry has set out on an ambitious path to become carbon neutral.
The coronavirus crisis caused by the Covid-19 pandemic has uncovered problems that have been smoldering beneath the surface of the pharmaceutical industry — including CMOs/CDMOs and CROs — and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
In January, Schrödinger, a provider of integrated software solutions, and the life sciences company Bayer announced a 5-year technology alliance to develop a comprehensive de novo design solution to accelerate the discovery of innovative, high-quality drugs.
Andrew Badrot, CEO of C2 Pharma and a close observer of pharma industry trends, analyzes the current situation and how this pandemic may kick of changes in the pharma market.
Linde intends to further expand its hydrogen business by investing in electrolysis capacities and infrastructure.